Table 6 Association between CD4 + T cell infiltration and clinicopathological features of MTC

Gender

Male

85(45.5)

38(44.7)

47(55.3)

Female

102(54.5)

49(48.0)

53(52.0)

Age at diagnose(year)

≤ 52

101(54.0)

48(47.5)

53(52.5)

>52

86(46.0)

39(45.3)

47(54.7)

Heredity

Hereditary

39(20.8)

12(30.8)

27(69.2)

sporadic

148(79.2)

75(50.7)

73(49.3)

Multifocal

Yes

55(29.4)

23(41.8)

32(58.2)

No

132(70.6)

64(48.5)

68(51.5)

ETE

Yes

76(40.6)

33(43.4)

43(56.6)

No

111(59.4)

54(48.6)

57(51.4)

Bilateral lesions

Yes

20(10.7)

7(35.0)

13(65.0)

No

167(89.3)

84(50.3)

8349.7)

Tumor size(cm)

≤ 2

120(64.2)

52(43.3)

68(56.7)

2–4

57(30.5)

33(57.9)

24(42.1)

>4

10(5.3)

2(20.0)

8(80.0)

pT stage

T1/T2

108(57.8)

53(49.1)

55(50.9)

T3/T4

79(42.2)

34(43.0)

45(57.0)

pN stage

N0

87(46.5)

36(41.4)

51(58.6)

N1a

26(13.9)

17(65.4)

9(34.6)

N1b

74(39.6)

34(45.9)

40(54.1)

8th TNM stage

I/II

77(41.2)

34(44.2)

43(55.8)

III/IV

110(58.8)

53(48.2)

57(51.8)

Coexist HT

Yes

24(12.8)

10(41.7)

14(58.3)

No

163(87.2)

77(47.2)

86(52.8)

Pathology

Only MTC

105(56.1)

3(41.0)

62(59.0)

With adenomatous goiter

9(4.8)

5(55.6)

4(44.4)

With nodular goiter

51(27.3)

28(54.9)

23(45.1)

With PTC

22(11.8)

11(50.0)

11(50.0)

Recurrence

Yes

22(11.8)

7(31.8)

15(68.2)

No

165(88.2)

80(48.5)

85(51.5)

Biochemical cure

Yes

98(52.4)

51(52.0)

47(48.0)

No

89(47.6)

36(40.4)

53(59.6)

IDO2 expression

Low

110(58.8)

40(36.4)

70(63.6)

High

77(41.2)

47(61.0)

30(39.0)